共 152 条
- [83] The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses [J]. ONCOIMMUNOLOGY, 2015, 4 (09): : 1 - 2
- [85] Rationale for anti-GITR cancer immunotherapy [J]. EUROPEAN JOURNAL OF CANCER, 2016, 67 : 1 - 10
- [86] Development of TLR9 agonists for cancer therapy [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) : 1184 - 1194